Loading...
Tobacco smoking is a permissive factor in the development of multiple sclerosis (MS), but the impact on the clinical course has not been established (NEJM JW Neurol Aug 3 2005). Investigators used data from a region-based U.K. MS clinic that included 895 complete cases with a median 15 years of follow-up. Study covariates included age at first clinical manifestation of disease, disease subtypes (e.g., relapsing or progressive), and treatment duration <1 year or ≥1 year. Smoking status was assessed during the clinic visit associated with the first clinical event and categorized as nonsmoker, ex-smoker, or current smoker.
Using the MS Severity Score, those who ever smoked were significantly more likely to be in the most severely disabled quartile of this scale (57% ever-smokers vs. 35% never-smokers). Compared with never-smokers, ever-smokers were 34% more likely to develop moderate disability in at least one system (Expanded Disability Status Scale score [EDSS] of 4.0) and 25% more likely to progress to require use of a cane to ambulate (EDSS = 6.0). Ex-smokers had a lower risk for disability than current smokers, a 35% reduction in risk for reaching EDSS 4.0, and a 31% reduction in risk for reaching EDSS 6.0.
Manouchehrinia A et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 2013 Jul; 136:2298. (http://dx.doi.org/10.1093/brain/awt139)
Comment
Multiple sclerosis patients should be counseled about the plethora of health risks with regard to smoking, which now include an increased disability progression to use of a cane. Although ever-smokers (i.e., ex-smokers and current smokers) had a higher overall risk than those who never smoked, those who had quit fared better than those who were current smokers. This potential benefit gives patients with MS additional incentive to try to quit.
Because smoking was assessed only at the start of the disease, future studies should evaluate the longitudinal effects of smoking status on disability over time. This could help differentiate whether smoking negatively affects the inflammatory stage, the neurodegenerative stage, or both.